insights_auto
Outlook: 14.3% bullish·19.1% bearish
Go to analysischevron_right
GSK:NYSE
GSK plc
US$47,03
arrow_downward
-0,32%(-0,15) 1D
US$47,16
arrow_upward
+0,28% (+0,13)bedtimeAfter hours
Closed: 2 ຕ.ລ., 16 ໂມງ 0 ນາທີ 03 ວິນາທີ GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
US$47,08
High
US$47,16
Low
US$46,84
Mkt. cap
96,02 ຕື້
Avg. vol.
3,18 ລ້ານ
Volume
5,35 ລ້ານ
Dividend
3,86%
Quarterly dividend
US$0,45
Ex-dividend date
13 ສ.ຫ. 2026
P/E ratio
15,10
52-wk high
US$61,70
52-wk low
US$42,84
EPS
US$3,12
Beta
0,25
Shares outstanding
2,02 ຕື້
No. of employees
67 ພັນ
Open
US$47,08
High
US$47,16
Low
US$46,84
Mkt. cap
96,02 ຕື້
Avg. vol.
3,18 ລ້ານ
Volume
5,35 ລ້ານ
Dividend
3,86%
Quarterly dividend
US$0,45
Ex-dividend date
13 ສ.ຫ. 2026
P/E ratio
15,10
52-wk high
US$61,70
52-wk low
US$42,84
EPS
US$3,12
Beta
0,25
Shares outstanding
2,02 ຕື້
No. of employees
67 ພັນ
News stories
From web sources and news partners
Traders Union
·
12 ຊົ່ວໂມງກ່ອນ
Voting rights update pressures GSK stock near GBX1,847 resistance
Stock Traders Daily
·
20 ຊົ່ວໂມງກ່ອນ
The Technical Signals Behind (GSK) That Institutions Follow
AD HOC NEWS
·
1 ມື້ກ່ອນ
GSK stock after-hours at EUR 21.03: minus 1.36 percent versus prior close
TipRanks
·
1 ມື້ກ່ອນ
GSK Updates Market on Total Voting Rights and Share Capital
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66,8 ພັນ
Founded27 ທ.ວ. 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com